Panitumumab Biosimilar - Research Grade

Human

EGFR

>1mg/ml

Human IgG2 kappa

Humanized

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Zalutumumab Biosimilar - Research Grade (ICH5116), Necitumumab Biosimilar - Research Grade (ICH5121), Depatuxizumab Biosimilar - Research Grade (ICH5294), Becotatug Biosimilar - Research Grade (ICH5378), Demupitamab Biosimilar - Research Grade (ICH5473), Futuximab Biosimilar - Research Grade (ICH5560), Imgatuzumab Biosimilar - Research Grade (ICH5600), Laprituximab Biosimilar - Research Grade (ICH5626), Losatuxizumab Biosimilar - Research Grade (ICH5657), Modotuximab Biosimilar - Research Grade (ICH5691), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P00533

1956

RRID:AB_2921543

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of panitumumab, engineered around the epidermal growth factor receptor (EGFR) and provided strictly for research use. As a fully human IgG2 kappa molecule directed against the EGFR ectodomain, it reproduces the antigen-binding behaviour of the originator biologic without being intended for any clinical, human, or veterinary application. It is a useful reagent for laboratory work: an isotype- and target-matched tool for receptor-binding and blocking assays, a positive control in EGFR immunoassays, a benchmark in comparability or bioanalytical method development, and a building block for antibody-drug-conjugate or bispecific engineering and Fc-function studies. Because IgG2 mediates comparatively weak ADCC, it also serves as a contrast reagent against IgG1-format anti-EGFR analogs. The material is supplied unconjugated at research grade with low endotoxin (typically under 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and is available in bulk milligram-to-gram quantities suitable for in-vitro and preclinical experimentation. It is not the clinical drug and carries no therapeutic claim. EGFR (also called HER1 or ErbB1; UniProt P00533) is a single-pass transmembrane receptor tyrosine kinase and the founding member of the ErbB/HER family. Ligands such as EGF, TGF-alpha, amphiregulin, and epiregulin bind its extracellular domain, driving receptor dimerisation (homodimers or heterodimers with HER2, HER3, or HER4) and trans-autophosphorylation of the cytoplasmic kinase domain. The resulting phosphotyrosines recruit adaptors that activate the RAS-RAF-MEK-ERK, PI3K-AKT, and STAT pathways, promoting proliferation, survival, migration, and angiogenesis. EGFR is frequently overexpressed, amplified, or mutated in epithelial cancers including colorectal, head and neck, lung, and pancreatic tumours, making its extracellular ligand-binding region a validated target for blocking antibodies that prevent ligand engagement and receptor activation.

Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, ERBB, ERBB1, HER1

Detects human EGFR. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Panitumumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0050

Panitumumab (anti-EGFR) Biosimilar

Q: Is the Panitumumab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Panitumumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Panitumumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Panitumumab that binds human EGFR; for research use only (RUO).